drugset
drugset / Trial / NCT00368602

Beta Blocker for Chronic Wound Healing

NCT00368602 ↗

Phase 2 Terminated 40 enrolled University of California, Davis
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of treatment of chronic cutaneous ulcers and burn wounds with topical beta adrenergic antagonists (Timoptic®).

Timeline

Start
2005-06
Primary completion
2007-06
Completion
2007-06

Outcome

Outcome not reported

Stopped (Business): “Lack of funding.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Timolol Other / unclassified — Topical

Indications

ulcer disease